| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3902216 | Urology | 2012 | 4 Pages |
Abstract
Our data suggest that teratoma or viable NSGCT is present in approximately one-third of patients undergoing resection of residual ERP disease. The presence of residual ERP teratoma and viable NSGCT predicts for cancer progression independent of RP histology.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Timothy A. Masterson, Bobby Shayegan, Brett S. Carver, Dean F. Bajorin, Darren R. Feldman, Robert J. Motzer, George J. Bosl, Joel Sheinfeld,